Treatment options for tumor progression after initial immunotherapy in advanced non-small cell lung cancer: A real-world study.

ABSTRACT:

Objective

Whether to continue administering immunotherapy to patients with advanced non-small cell lung cancer (NSCLC) who have experienced tumor progression remains controversial after immunotherapy. The aims were to explore survival outcomes after further immunotherapy post-progression and to determine the optimal combination therapy in such cases.

Methods

Overall, 507 patients with NSCLC who underwent immunotherapy and experienced tumor progression were retrospectively divided into Immuno-combination and No-immuno groups according to whether additional combination therapy involving immunotherapy was administered post-progression. Progression-free survival (PFS) and overall survival (OS) were evaluated. Subgroup analyses were performed according to the different treatment

SUBMITTER: Li Y 

PROVIDER: S-EPMC11403516 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature